Oregon Psilocybin One Year In: What the First 12 Months of Legal Service Centers Actually Looked Like

It has been just over a year since Oregon's first psilocybin service center opened its doors to adult clients, and the program that voters authorized in 2020 has had enough operational runway for the data to start telling a real story. The headlines during the run-up focused on what Measure 109 would mean for mental health care, for the broader drug policy debate, and for the small but committed group of entrepreneurs who bet their capital on a supervised-use framework that no state had attempted before. The reality a year in is more interesting than any of those storylines, partly because it is more complicated, and partly because the Oregon Health Authority has been unusually transparent about publishing what the program is and is not delivering.

This article walks through what Measure 109 actually built, who is using the licensed service centers, how dosing and pricing have played out in practice, what published adverse-event data and operator interviews show about the client experience, and the 2026 legislative course-corrections that are reshaping the program as it heads into year two. It is not advocacy for or against the Oregon model. It is an attempt to summarize, with citations, what is now knowable on the first anniversary.

What Measure 109 Actually Built

Oregon Measure 109, passed by voters in November 2020 and amended by the legislature in 2023 to fix implementation gaps, did three things at once. It created a state-licensed category of psilocybin service center where adults 21 and older can consume psilocybin under the supervision of a state-licensed facilitator. It created a state-licensed category of psilocybin manufacturer that can cultivate psilocybin-producing mushrooms and process them into doses for service center use. It created a state-licensed category of psilocybin laboratory that tests the product. The measure did not legalize psilocybin possession in general. It did not authorize retail sales. It did not allow clients to take product home. Every dose is consumed on the licensed service center premises, in the presence of the licensed facilitator, in a session that typically runs six to eight hours.

The two-year ramp from ballot measure to first license was longer than the campaigns suggested it would be. The Oregon Health Authority spent 2021 and 2022 writing administrative rules, selecting a Product Tracking System vendor, and standing up an advisory board. The first facilitator licenses were issued in 2023. The first manufacturer and laboratory licenses followed. The first service center license was issued in mid-2023, and the doors opened for clients in earnest in late 2023. Oregon thus went from a 2020 ballot authorization to an operational supervised-use program in roughly three and a half years, which is fast by state-level public health standards but slower than the most enthusiastic pre-passage marketing implied.

The program is intentionally narrow. It covers psilocybin only. Ayahuasca, DMT, MDMA, ibogaine, mescaline, ketamine, and any other psychedelic compound are out of scope. There is no clinical diagnosis required for entry. There is no prescription. A client does not need a referral from a physician or a therapist. The framework is closer to a regulated, supervised adult-use experience than to a medical treatment pathway, and the marketing from most service centers reflects that positioning, leaning on themes of personal growth, life transitions, and wellness rather than clinical mental health outcomes.

How Many Centers Are Operating

The Oregon Health Authority maintains a publicly searchable license registry, the Psilocybin Services License Information page, that shows how many of each license type are active, pending, or expired. As of mid-2026, the registry shows a small but steady number of fully licensed service centers, in the high teens to low twenties depending on the snapshot date, alongside a larger pool of manufacturers and a handful of laboratories. The center count is well below what some early operator projections anticipated and well above what the most skeptical observers expected.

The growth trajectory has been gradual rather than explosive. New service center licenses have trickled in month over month through 2024 and 2025, with a noticeable uptick in late 2025 as the first cohort of operators who had been working through the licensing process for two years finally opened. Manufacturer licenses have grown faster than service center licenses, in part because each service center typically sources from a single manufacturer and in part because the manufacturing application has been somewhat less onerous in practice than the service center application. The number of licensed facilitators, by contrast, has grown the fastest of all three license categories. Hundreds of facilitators now hold active licenses, with many of them operating as independent contractors serving multiple service centers rather than being tied to a single operator.

The gap between the number of licensed operators and the number of approved applicants is the more interesting story. A meaningful number of operators have received approval to operate but have not yet opened. Some have cited capital constraints, since the build-out cost for a compliant service center, including the required preparation and dosing rooms, accessibility features, ventilation, and security, runs into the high six figures. Some have cited local zoning friction. Some have cited the slow pace of client demand relative to their projections. The registry shows the number of approved-but-not-yet-open licenses as a separate category from the number actively serving clients, and that gap is one of the most useful numbers to watch in the program's second year.

Who Is Actually Walking In

OHA's quarterly psilocybin services reports, published on the Psilocybin Services Data and Statistics page, have begun to show a demographic profile that differs in important ways from the early program's public-facing projections. The most recent quarterly snapshot as of mid-2026 indicates that clients skew older than the early program marketing implied. The largest single age band is 40 to 59, followed by 30 to 39 and 60 and older. Clients under 30 are a small share of the total. This is the opposite of what the most enthusiastic program advocates suggested during the campaign, when the imagined client base leaned heavily toward younger adults seeking new experiences.

The reported primary reasons for attending cluster around mental health and life transitions. Anxiety, depression, grief, and end-of-life concerns appear frequently in the intake data that service centers are required to report to OHA. Prior psychedelic experience is common: a majority of clients report having used psilocybin or another classic psychedelic at least once before attending a service center. Very few clients are entirely new to psychedelics. The implication is that the program is, in practice, serving a population that has already self-selected into psychedelic interest and is now using the legal framework as a way to access the experience with clinical-grade product, a licensed facilitator, and a defined legal status, rather than as a way to introduce psychedelics to a population that had never considered them.

Demographic data on race, ethnicity, and income is more limited in the public reporting, which is one of the gaps that advocates and legislators have flagged. The equity-fund mechanism built into Measure 109, designed to subsidize service costs for low-income clients and for clients from communities historically harmed by drug enforcement, has not yet produced the kind of access numbers its proponents hoped for. The fund has been slow to scale, in part because the application and disbursement process has been heavier than the legislature initially projected. Rural and urban service patterns also diverge: the bulk of operating service centers are clustered in and around Portland, with a handful on the coast and in the Willamette Valley and very few east of the Cascades. The geographic distribution has been a recurring point of legislative attention.

Dosing Protocols in Practice

Measure 109 does not prescribe a specific clinical protocol. There is no mandated dose, no mandated session length, no mandated facilitator-to-client ratio written into statute or administrative rule. The Oregon Health Authority's administrative rules set minimum standards for facilitator training, dosing room requirements, adverse-event reporting, and client screening, but they leave the actual dose, the session structure, and the integration support to the discretion of the operator and the facilitator within those bounds.

In practice, the dose range used by most licensed service centers is in the neighborhood of 25 milligrams of synthetic psilocybin equivalent, with some variation up and down based on client experience, the operator's philosophy, and the form of the product. The product itself is, for most centers, a capsule of known psilocybin content manufactured by a licensed producer and tested by a licensed laboratory. Whole dried mushroom, the form most often associated with retreat and ceremonial use, is permitted under the rules but less common in the Oregon licensed context because of the manufacturing and testing requirements. A handful of operators use sub-perceptual or low-dose protocols marketed as "microdose sessions," but the dominant offering is a full-dose preparation and dosing session that runs the better part of a day.

Session structure has converged on a familiar shape. Clients complete a medical and psychological screening before booking. They attend a preparation session, typically in the week before dosing, with the facilitator who will be present during the session. They arrive at the service center on dosing day and spend roughly six to eight hours in the supervised dosing room, with the facilitator present throughout. They return for one or more integration sessions in the weeks after. The integration piece varies the most across operators. Some build in multiple integration contacts as a baseline; some treat integration as optional or as a paid add-on. Published operator interviews, including pieces in Oregon Public Broadcasting (OPB) and the Oregonian, have consistently highlighted integration as both the part of the work that clients find most valuable and the part that operators find hardest to fund.

Pricing and Access

The session price for a full-dose Oregon psilocybin experience at a licensed service center ranges roughly from $1,000 to $3,000 or more, with the median sitting near the lower end of that range and the higher end occupied by operators who bundle extensive preparation, longer sessions, or multiple integration contacts into the program. Pricing is set by the individual operator and is not regulated by OHA. There is no insurance coverage pathway in place, and the program is not designed as a reimbursable clinical treatment. Clients pay out of pocket.

The pricing has produced two predictable outcomes. The first is that the client base skews toward adults with disposable income, which the demographic data confirms. The second is that the program's equity goals, which were a central part of the original Measure 109 campaign, have been hard to achieve at the current price points. The equity fund mechanism has begun to disburse grants that subsidize service costs for income-eligible clients, but the number of clients reached through the equity pathway is a small share of total clients served. Sliding-scale programs exist at some service centers but are uneven and operator-dependent.

Rural and urban access has diverged in ways that mirror the broader American healthcare geography. Portland and the surrounding metro area have a dense cluster of service centers, multiple manufacturers, and at least one laboratory. The coast has a handful. The Willamette Valley has several. Central Oregon, Eastern Oregon, and Southern Oregon have very few. Clients who would otherwise have to drive three or more hours each way to reach a service center often do not. The legislature's HB 3412, discussed below, is partly a response to this access gap.

Reported Outcomes and Adverse Events

The Oregon Health Authority publishes an ongoing adverse-event summary, most recently on the Psilocybin Adverse Event Reports page, which has become the single most-cited dataset on the program's actual safety record. As of mid-2026, the cumulative adverse event count across all licensed service centers is in the low double digits, with the most common categories being transient psychiatric symptoms (anxiety, dissociation, panic during the session), cardiovascular symptoms in clients with underlying conditions who were not adequately screened, and behavioral issues that required facilitator intervention. No client deaths have been reported in the licensed Oregon program as of the most recent OHA summary.

The distinction between "experiential difficulty" and "adverse event" is one that the public reporting has had to make explicit. Most high-dose psilocybin sessions involve some period of psychological discomfort. The Oregon framework treats that discomfort as a normal part of the experience that the facilitator is trained to support, rather than as an adverse event per se. An adverse event, in OHA's reporting taxonomy, is an occurrence that required medical intervention, resulted in hospitalization, resulted in lasting psychological harm, or involved a safety threat to the client or to others. The handful of adverse events reported to date have skewed toward the medical-intervention category and have generally involved clients with undisclosed or inadequately screened pre-existing conditions.

What the public data does not capture is at least as important as what it does. OHA does not publish client-reported outcome data, which means there is no public dataset on how many clients experienced meaningful improvement in their reported reason for attending. There is no published longitudinal follow-up. There is no standardized measure of integration outcomes. Operator-reported testimonials fill some of this gap but are not a substitute for independent measurement. The Associated Press, OPB, and the Oregonian have all done reporting on individual client experiences, and those stories have been largely positive, but they are not a population-level outcome dataset. The lack of a public outcomes registry is one of the more substantive critiques from researchers who support the program's intent but want better data on what it is actually producing.

Regulatory Course-Corrections

The 2025 and 2026 Oregon legislative sessions produced a series of changes to the Measure 109 framework that are best understood as course-corrections rather than reversals. The first, House Bill 3412 passed in early 2026, opens psilocybin services to licensed healthcare providers, including physicians, nurse practitioners, and licensed psychologists, allowing them to offer psilocybin services under their existing healthcare licenses without needing to obtain the standalone service center license. The aim of the bill, on its face, is to expand the number of providers who can offer services and to fold psilocybin into the existing healthcare workforce rather than requiring a parallel facilitator-only infrastructure. The bill's effects on year two will depend heavily on how quickly healthcare providers take up the option and on how OHA writes the administrative rules that govern the integration.

House Bill 3448, also passed in 2026, focuses on transparency for manufacturers. It requires licensed psilocybin manufacturers to publish their testing results, their pricing, and their production volumes, on a schedule set by OHA. The bill was driven by operator and legislator concerns that the manufacturer side of the market had consolidated quickly and that service centers had limited visibility into either the cost structure or the supply reliability of their upstream suppliers. Whether HB 3448 produces more competition or simply more paperwork will be one of the things to watch in year two.

The 2024 partial repeal of Measure 110, Oregon's 2020 personal-possession decriminalization measure, also shapes the psilocybin program context. Measure 110's recriminalization did not directly affect the psilocybin services framework, which was a separate ballot measure, but it did reset the broader state drug policy conversation and made legislators more attentive to the specific data on the psilocybin program. OHA's administrative rule amendments through 2025 and 2026 have tightened facilitator training requirements, clarified adverse-event reporting timelines, and adjusted the client screening guidance. None of these changes reversed the program. All of them narrowed the gap between the original framework and the operational reality.

What One Year Tells Us About the Policy Path

The honest read of year one is that Oregon Measure 109 has produced a working, supervised-use program that is meaningfully safer than the unregulated retreat alternatives covered in our piece on retreat legal gray zones, while falling well short of the access and equity outcomes its most enthusiastic proponents projected. The program is licensed, inspected, and reported on. The product is tested. The facilitators are trained. The adverse-event rate is low. The pricing is high, the geographic distribution is uneven, the client demographic skews older and wealthier than the campaign imagined, and the public outcomes data is thinner than researchers would like.

Compared to Colorado's healing-center launch under Proposition 122, which began licensing operators in 2024 and 2025 and is in a different stage of operational maturity, Oregon's program is further along but is also running into the limitations of a facilitator-and-service-center model that the Colorado framework is actively trying to learn from. New Mexico's medical psilocybin framework, which took a different approach focused on medical licensure and prescription pathways, is moving more slowly and has produced fewer licensed providers to date but may offer better insurance-coverage and equity outcomes once it scales. The federal rescheduling conversation, which has moved in fits and starts through DEA hearings and FDA recommendations in 2024 and 2025, would change the entire state-level landscape if it produces a Schedule III or Schedule IV reclassification, but the timeline and the outcome remain uncertain.

The most useful takeaway from year one is that building a legal, regulated, supervised-use program for a previously prohibited substance is a multi-year project that produces more useful data the longer it runs. Oregon now has that data, and the legislative and administrative responses through 2026 are clearly informed by it. The questions for year two are whether HB 3412 produces meaningful new provider participation, whether HB 3448 produces more competitive supply, whether the equity fund reaches more clients, and whether OHA begins publishing the outcomes data that researchers have been asking for. None of those questions have an answer yet. All of them will, by the second anniversary.

For background on the substance itself, see our explainers on psilocybin and psilocybin therapy. For the dose ranges that licensed Oregon centers are using, see our dosage guide. For context on how the Oregon framework compares to the unregulated retreat landscape, see our piece on psychedelic retreat legal gray zones. For the broader US state-by-state picture, see our psychedelic laws map.

This article is informational and reflects Oregon psilocybin program data as of August 2026. Program rules, license counts, and legislative outcomes change. Verify current status through the Oregon Health Authority before making any decisions based on this article.

This article is informational and does not constitute medical or legal advice. Psilocybin services in Oregon are available only through licensed service centers, and possession outside that framework remains a federal offense.